Results 31 to 40 of about 353,326 (255)

Bucillamine prevents cisplatin-induced ototoxicity through induction of glutathione and antioxidant genes. [PDF]

, 2015
Bucillamine is used for the treatment of rheumatoid arthritis. This study investigated the protective effects of bucillamine against cisplatin-induced damage in auditory cells, the organ of Corti from postnatal rats (P2) and adult Balb/C mice.
Choe, Seong-Kyu, Ho Hur, Joon, Kim, Hyung-Jin, Kim, Se-Jin, Lee, Joon No, Lim, David J, Moon, Sung K, Oh, Gi-Su, Park, Channy, Park, Raekil, So, Hong-Seob, Yoo, Su-Jin   +11 more
core   +2 more sources

PRDX1 activates autophagy via the PTEN-AKT signaling pathway to protect against cisplatin-induced spiral ganglion neuron damage

Autophagy, 2021
Spiral ganglion neurons (SGNs) are auditory neurons that relay sound signals from the inner ear to the brainstem. The ototoxic drug cisplatin can damage SGNs and thus lead to sensorineural hearing loss (SNHL), and there are currently no methods for ...
Wenwen Liu, Lei Xu, Xue Wang, Daogong Zhang, Gaoying Sun, Man Wang, Mingming Wang, Yue-chen Han, R. Chai, Haibo Wang   +9 more
semanticscholar   +1 more source

1-Hydroxy-8-methoxy-anthraquinon reverses cisplatin resistance by inhibiting 6PGD in cancer cells

Open Life Sciences, 2019
Targeting 6-phosphogluconate dehydrogenase (6PGD) can inhibit cancer cell proliferation and tumor growth. However, the relationship between 6PGD and cisplatin resistance still needs further study.
Zhang Huamin, Zhang Haowei, Wang Sihui, Ni Zhihai, Wang Tiejun   +4 more
doaj   +1 more source

Epigallocatechin-3-gallate, a prototypic chemopreventative agent for protection against cisplatin-based ototoxicity [PDF]

, 2017
Cisplatin-induced ototoxicity is one of the major factors limiting cisplatin chemotherapy. Ototoxicity results from damage to outer hair cells (OHCs) and other regions of the cochlea.
Bhatta, Puspanjali, Borse, Vikrant, Dhukhwa, Asmita, FH Al Aameri, Raheem, Ghosh, Sumana, Kaur, Tejbeer, Lowy, Michelle, Mukherjea, Debashree, Ramkumar, Vickram, Rybak, Leonard P, Sheehan, Kelly, Sheth, Sandeep, Tupal, Srinivasan   +12 more
core   +2 more sources

Cisplatin liposome and 6-amino nicotinamide combination to overcome drug resistance in ovarian cancer cells [PDF]

, 2018
Ovarian cancer is an aggressive and lethal cancer usually treated by cytoreductive surgery followed by chemotherapy. Unfortunately, after an initial response, many patients relapse owing mainly to the development of resistance against the standard ...
Catanzaro, Daniela, Cocetta, Veronica, Montopoli, Monica, Nicolosi, Silvia, Pagetta, Andrea, Pasut, Gianfranco, Ragazzi, Eugenio, Salvalaio, Marika   +7 more
core   +1 more source

Oxaliplatin induces drug resistance more rapidly than cisplatin in H69 small cell lung cancer cells [PDF]

, 2006
Cisplatin produces good responses in solid tumours including small cell lung cancer (SCLC) but this is limited by the development of resistance. Oxaliplatin is reported to show activity against some cisplatin-resistant cancers but there is little known ...
A Ibrahim, A Rennicke, AB Sandler, AP Jekunen, BA Jansen, BA Teicher, Britta K. Stordal, BS Burns, C Kollmannsberger, C Kollmannsberger, CR Culy, D Pectasides, D Pectasides, DC Marks, G Belvedere, G Lenz, G Tisman, GA Hospers, H Kawai, H Kuroda, HD Preisler, HD Preisler, IS Song, J Liu, JM Woynarowski, JM Woynarowski, K Suzukake, K Yamamoto, KV Grech, L Pendyala, L Poulain, M Abal, M Markman, M Mishima, Mary W. Davey, N Jain, N Savaraj, N Thatcher, O Rixe, P Chollet, P Soulie, PJ Kuppen, PR Twentyman, R Sockalingam, RD Christen, Ross A. Davey, S Hector, S Ohta, SG Chaney, SL Lai, SW Johnson, T Fojo, T Moritaka, T Tashiro, V Dieras, VL Locke, WS Hong, Z El Akawi, Z Wang   +58 more
core   +2 more sources

Identification of genes associated with cisplatin resistance in human oral squamous cell carcinoma cell line

BMC Cancer, 2006
Background Cisplatin is widely used for chemotherapy of head and neck squamous cell carcinoma. However, details of the molecular mechanism responsible for cisplatin resistance are still unclear.
Zhang Ping, Zhang Zhiyuan, Zhou Xiaojian, Qiu Weiliu, Chen Fangan, Chen Wantao   +5 more
doaj   +1 more source

Valproic acid treatment attenuates cisplatin‐induced kidney injury by suppressing proximal tubular cell damage

Clinical and Translational Science, 2023
Cisplatin treatment is effective against several types of carcinomas. However, it frequently leads to kidney injury, which warrants effective prevention methods.
Toshihiko Yoshioka, Mitsuhiro Goda, Masaya Kanda, Sayuri Itobayashi, Yugo Sugimoto, Yuki Izawa‐Ishizawa, Kenta Yagi, Fuka Aizawa, Koji Miyata, Takahiro Niimura, Hirofumi Hamano, Takumi Sakurada, Yoshito Zamami, Keisuke Ishizawa   +13 more
doaj   +1 more source

Protein flexibility is key to cisplatin crosslinking in calmodulin [PDF]

, 2012
Chemical crosslinking in combination with Fourier transform ion cyclotron resonance mass spectrometry (FTICR MS) has significant potential for studying protein structures and proteinprotein interactions.
Jimenez-Roldan, J. Emilio, Li, Huilin, O'Connor, Peter B., Römer, Rudolf A., Sadler, P. J., Wells, Stephen A., Zhao, Yao, (Researcher in chemistry)   +6 more
core   +1 more source

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.

Journal of Clinical Oncology, 2008
PURPOSE Cisplatin plus gemcitabine is a standard regimen for first-line treatment of advanced non-small-cell lung cancer (NSCLC). Phase II studies of pemetrexed plus platinum compounds have also shown activity in this setting. PATIENTS AND METHODS This
G. Scagliotti, P. Parikh, J. von Pawel, B. Biesma, J. Vansteenkiste, C. Manegold, P. Serwatowski, U. Gatzemeier, R. Digumarti, M. Zukin, J. S. Lee, A. Mellemgaard, Keunchil Park, S. Patil, J. Rolski, T. Goksel, F. de Marinis, L. Simms, K. Sugarman, D. Gandara   +19 more
semanticscholar   +1 more source